The Scientific Board (SB) is the decision-making organ of the TOC consortium and will decide all issues not covered by the consortium agreement. The SB meets physically once in a year to monitor the progress. At this meeting decision about including new centers will be taken. Further more the SB will decide which projects will be performed and prioritized. To ensure a fair cooperation of all participants, all centers providing samples for a specific project, will be added as co-authors in all publications referring to these results. Every center will have one or two representatives in the Scientific Board, depending on the volume of patients included within the bio-bank.

• Assist. Professor Patriciu Achimas, Oncological Institute, Cluj-Napoca, Romania
• Professor Dr Andreas Du Bois, Klinik Essen Mitte, Essen, Germany
• Dr. Elena Ioana Braicu, Charité Medizinische Universität, Berlin, Germany
• Assoc. Professor Oumar Camara, Hufeland Klinikum, Bad Langensalza, Germany
• Professor Dr. Nicole Concin, Medizinische Universität Innsbruck, Austria
• Assoc. Professor Silvia Darb-Esfahani, Charité Medizinische Universität, Berlin, Germany
• Professor Christina Fotopoulou, Imperial College, London, UK
• Professor Dr. Annette Hasenburg, Medizinische Universität Freiburg, Germany
• Assoc. Professor Dominique Könsgen-Mustea, Medizinische Universität, Greifswald, Germany
• Professor Dr. Ivo Meinhold-Heerlein, Uniklinik RWTH Aachen, Germany
• Assoc. Professor Sven Mahner, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
• Professor Dr. Alexander Mustea, Medizinische Universität, Greifswald, Germany
• Professor Dr. Alexander Reinthaller, Medizinische Universität Wien, Vienna, Austria
• Professor Dr. Jalid Sehouli, Charité Medizinische Universität, Berlin, Germany
• Professor Dr. Dimitrie Sofroni, Oncological institute, Chisinau, Republic of Moldavia
• Professor Dr. Robert Zeillinger, Medizinische Universität Wien, Vienna, Austria
• Prof. Dr. Ignace Vergote, Catholic University Leuven, Belgium
• Professor Dr. Pauline Wimberger, Universitätsklinikum Carl Gustav Carus, Dresden, Germany

Leader: Elena Ioana Braicu, MD
Speaker: Prof. Dr. Jalid Sehouli
Iulia Ignat
Hagen Kulbe

Leader: Ao.Univ.-Prof. Dr. Robert Zeillinger

Leader: Alexander Reinthaller

Leader: Prof. Ignace Vergote

Leader: Prof. Alexander Mustea
Dominique Mustea-Könsgen, MD, PhD

Leader: Prof. Christina Fotopoulou
Prof. Hani Gabra

Leader: Sven Mahner, MD, PhD
Fabian Trillsch

Leader: Annette Hasenburg

Leader Prof. Pauline Wimberger

Leader: Prof. Andreas du Bois

Leader: Prof. Ivo Meinhold-Heerlein

Leader: Ass. Prof. Patriciu Achimas-Cadariu

Leader:

Leader: Oumar Camara, PhD, MD

Leader: Prof. Nicole Concin

The Innsbruck Medical University is dedicated to patient care, research and education. This comprehensive centre has recently been established with a strong collaboration between the various different disciplines. The Department of Obstetrics and Gynaecology, chaired by Prof. Christian Marth, is a large tertiary centre in gynaecologic oncology with more than 500 gynaecologic cancer patients per year. Translational research is facilitated by excellent laboratory facilities with ca. 500 m² laboratory area. Since 1985 a tissue and serum bank has been built with tissue samples from more than 5,000 cancer patients and about 250,000 serum samples. The Department participates and organises ovarian cancer trials from phase I to phase III with the help of the integrated Austrian-AGO trial centre. 

The BCRT has a highly interactive research program based on a consortium of internationally acknowledged experts in both basic and clinical science with a track record of successful scientific interaction. The program comprises work in four medical research fields linked to overlapping platforms on basic, biomaterials, and translational research. Initially, the Center is putting particular emphasis on research and clinical programs related to musculoskeletal and immunological applications. In additon, the Center will focus on regenerative therapies concerning the cardiovascular system and nervous system.

The Max Planck Institute for Infection Biology in Berlin is a research center which focuses on understanding the biology of human pathogens and how they affect human health. The central question of pathogen host interaction is addressed using a variety of multidisciplinary approaches and state of the art methodologies from the fields of molecular biology, biochemistry, proteomics, imaging, high-throughput analysis etc. The department of Molecular Biology investigates, among others the long term effects of the gram-negative genital pathogen Chlamydia trachomatis on human host tissues (e.g. fallopian tubes, cervix) and the role it plays in the development of pathology.